3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea,
BGJ398,
NVP-BGJ398,
872511-34-7,
NVP-BGJ398,
Infigratinib,
BGJ398,
BGJ-398,
BGJ 398,
BGJ398 (NVP-BGJ398),
UNII-A4055ME1VK,
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea,
A4055ME1VK,
CHEBI:63451,
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)-1-methylurea,
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)-1-methylurea,
C26H31Cl2N7O3,
CHEMBL1834657,
Infigratinib [INN],
3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea,
Tube728,
bgj398-nvp-bgj398,
NVP-BGJ389,
NVP-BGJ398(Infigratinib),
MLS006010953,
SCHEMBL374435,
GTPL7877,
QCR-48,
CHEMBL1852688,
DTXSID70236238,
EX-A057,
SYN1152,
BGJ398, NVP-BGJ398,
QADPYRIHXKWUSV-UHFFFAOYSA-N,
BGJ398, BGJ-398,
AOB87703,
BCP03602,
BGJ398 - NVP-BGJ398,
BDBM50355393,
FD5035,
MFCD22123241,
RW4152,
s2183,
ZINC72105034,
AKOS025149513,
AKOS032949944,
BCP9000399,
CS-0586,
DB11886,
RL05423,
SB16612,
KS-0000063C,
NCGC00274030-01,
NCGC00274030-11,
4CA-0927,
AC-28417,
AK187674,
AS-16290,
BC261938,
HY-13311,
SC-86751,
SMR004702757,
Urea, N'-(2,6-dichloro-3,5-dimethoxyphenyl)-N-(6-((4-(4-ethyl-1-piperazinyl)phenyl)amino)-4-pyrimidinyl)-N-methyl-,
BCP0726000187,
FT-0699366,
Y0313,
W-5856,
J-510477,
BRD-K42728290-001-01-8,
07J,
3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea,
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea,
FGFR inhibitors,
NVP-BGJ398 phosphate,
D03LWG,
cc-248,
2-fluoro-6-(thiophen-2-yl)pyridine,
ACN-054321,
A3014,
A3673,
A11159,
C568950,
1310746-10-1,
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea,